Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Trypanosoma cruzi | hexokinase, putative | 0.0963 | 1 | 0.5 |
Loa Loa (eye worm) | hexokinase | 0.0963 | 1 | 1 |
Schistosoma mansoni | hexokinase | 0.0963 | 1 | 0.5 |
Onchocerca volvulus | 0.0963 | 1 | 1 | |
Brugia malayi | Hexokinase family protein | 0.0963 | 1 | 1 |
Echinococcus granulosus | hexokinase type 2 | 0.0963 | 1 | 0.5 |
Trypanosoma brucei | hexokinase | 0.0963 | 1 | 0.5 |
Leishmania major | hexokinase, putative | 0.0963 | 1 | 0.5 |
Echinococcus granulosus | hexokinase | 0.0963 | 1 | 0.5 |
Trypanosoma brucei | hexokinase, putative | 0.0963 | 1 | 0.5 |
Plasmodium vivax | hexokinase, putative | 0.0963 | 1 | 0.5 |
Echinococcus multilocularis | hexokinase type 2 | 0.0963 | 1 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.0657 | 0.1468 | 0.1468 |
Loa Loa (eye worm) | hexokinase | 0.0963 | 1 | 1 |
Trypanosoma cruzi | hexokinase, putative | 0.0963 | 1 | 0.5 |
Plasmodium falciparum | hexokinase | 0.0963 | 1 | 0.5 |
Toxoplasma gondii | hexokinase | 0.0963 | 1 | 0.5 |
Echinococcus granulosus | hexokinase | 0.0963 | 1 | 0.5 |
Onchocerca volvulus | 0.0963 | 1 | 1 | |
Entamoeba histolytica | hexokinase 1 | 0.0963 | 1 | 0.5 |
Entamoeba histolytica | hexokinase 2 | 0.0963 | 1 | 0.5 |
Loa Loa (eye worm) | hexokinase type II | 0.0963 | 1 | 1 |
Onchocerca volvulus | 0.0963 | 1 | 1 | |
Leishmania major | hexokinase, putative | 0.0963 | 1 | 0.5 |
Echinococcus multilocularis | hexokinase | 0.0963 | 1 | 0.5 |
Echinococcus multilocularis | hexokinase | 0.0963 | 1 | 0.5 |
Echinococcus granulosus | hexokinase | 0.0963 | 1 | 0.5 |
Treponema pallidum | hexokinase (hxk) | 0.0963 | 1 | 0.5 |
Trypanosoma brucei | hexokinase | 0.0963 | 1 | 0.5 |
Echinococcus multilocularis | hexokinase | 0.0963 | 1 | 0.5 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.